Indications up for PET
Wednesday, 16 July, 2008
The Australian Government has expanded approved indications for Medicare reimbursement for PET imaging.
The inclusion of ovarian cancer, colorectal cancer and recurrent melanoma brings to a total of six the number of PET indications which are approved for reimbursement through Medicare.
One company poised to take advantage of this decision is Cyclopharm [ASX: CYC], which has already commenced development of two PET radiopharmacy sites.
The first is to be built at the Macquarie University Private Hospital, and should be completed in the first half of next year.
Organoid platform enables closer study of bat-borne viruses
Reconstructing bat organ physiology in the lab lets scientists explore how zoonotic viruses work...
Global study finds 250 genes linked to OCD
Researchers say they have found the genes linked to obsessive compulsive disorder (OCD), after...
TGA approves therapy for paediatric growth hormone deficiency
The TGA has approved SKYTROFA as a treatment for growth failure in children and adolescents aged...
